Trial Profile

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 22 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cobimetinib (Primary) ; Etrumadenant (Primary) ; Hyaluronidase (Primary) ; Motixafortide (Primary) ; Selicrelumab (Primary) ; Simlukafusp alfa (Primary) ; Tiragolumab (Primary) ; Tocilizumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel
Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Adverse reactions; Therapeutic Use
Acronyms Morpheus-Pancreatic Cancer; MORPHEUS-PDAC
Sponsors Roche

18 Apr 2025 Status changed from active, no longer recruiting to completed.
06 Feb 2025 Planned End Date changed from 31 Jan 2025 to 28 Feb 2025.
06 Feb 2025 Planned primary completion date changed from 31 Jan 2025 to 28 Feb 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com